Möchten Sie immer auf dem neuesten Stand bleiben?

Pune, June 10, 2022 (GLOBE NEWSWIRE) -- Assisted Reproductive Technology (ART) Market by Vendor Assessment, Technology Assessment, Partner & Customer Ecosystem, type/solution, service,...

AFM28 induced potent, effective, and specific anti-tumor activity against CD123-positive cells irrespective of mutational statusStudy demonstrated specific anti-tumor response even at low levels of...

– Treatment with PYRUKYND® Associated with Early and Robust Hemoglobin Responses in Phase 3 ACTIVATE and Extension Studies; Approximately One-Third of Patients Achieved Normal Hemoglobin Levels at...

MONTRÉAL, Québec, June 10, 2022 (GLOBE NEWSWIRE) -- IBEX Technologies Inc. (“IBEX” or the “Company”) (TSX Venture: IBT) today reported its financial results for the nine months ended April...

First RSV vaccine candidate to show statistically significant and clinically meaningful efficacy in adults aged 60 years and aboveThird AS01 adjuvanted vaccine containing QS-21 STIMULON to deliver...

Preclinical data demonstrate VIP152 as the most selective CDK9 inhibitor compared with other CDK9 inhibitors, with the most robust MYC mRNA downregulation Clinical data show improved selectivity,...

NOVATO, Calif., June 10, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...

Multiplex deletion of myeloid antigens CD33 and CLL-1 in human hematopoietic stem cells demonstrates potential of next-generation HSC transplants for treatment of acute myeloid leukemia Dual edited...

Ongoing experiments will evaluate the functionality and efficacy of GTB-7550 in vivoFuture studies will also involve assessments of GTB-7550 TriKE efficacy in other hematologic cancers BRISBANE,...

81% of evaluable patients achieved an objective responseDeep responses: 64% are CR/CRi, of which 86% achieved transfusion independenceRapid and durable responses: 91% by end of cycle 2, with 64% of...